Literature DB >> 23521493

Effect of repeated Campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes.

J Sung1, W Morales, G Kim, V Pokkunuri, S Weitsman, E Rooks, Z Marsh, G M Barlow, C Chang, M Pimentel.   

Abstract

BACKGROUND: Campylobacter jejuni infection is a leading cause of gastroenteritis and post infectious irritable bowel syndrome (PI-IBS). Unanswered questions include the role of cytokines, effects on gut flora, and why IBS is not more prevalent in countries with higher gastroenteritis rates. Therefore, we determined the effects of early and repeat C. jejuni infections on post infectious phenotypes, gut flora, and cytokine levels in a rat model of functional bowel and microbial changes.
METHODS: Sprague-Dawley rats were gavaged with 10(8)  cfu C. jejuni as juveniles and again as adults (J+/A+), as adults only (J-/A+), or vehicle (controls). Stool consistency during acute colonization, post infectious stool wet weight, total bacteria and Methanobrevibacter smithii levels in bowel segments, and ileal cytokines were evaluated. KEY
RESULTS: C. jejuni colonization was longer for first exposures as juveniles (43.4 ± 1.7 days) vs. adults (30.4 ± 3.5 days) (P < 0.01) and shortest for second exposures (10.5 ± 1.7 days, P < 0.05). Small intestinal bacterial overgrowth (SIBO) was more prevalent in J+/A+ (47%) than J-/A+ rats (26%) (P = 0.019), but J-/A+ rats had greater stool consistency alterations (P < 0.01). Ileal β-defensin 2, TLR-4, IL-8, and β-defensin 6 levels were increased in J-/A+ rats and further increased in J+/A+ rats; TNF-α was highest and IL6 lowest in J-/A+ rats. Total bacteria increased, and M. smithii decreased, with successive infections. CONCLUSIONS &amp; INFERENCES: We conclude that C. jejuni infection results in long-term alterations in small bowel flora, including methanogens. Mucosal defense mediators appear related to the number of infections, but not to SIBO development or the development of functional bowel phenotypes.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23521493     DOI: 10.1111/nmo.12118

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  7 in total

Review 1.  Campylobacter jejuni and associated immune mechanisms: short-term effects and long-term implications for infants in low-income countries.

Authors:  Amanda E Schnee; William A Petri
Journal:  Curr Opin Infect Dis       Date:  2017-06       Impact factor: 4.915

2.  Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.

Authors:  Walter Morales; Ali Rezaie; Gillian Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2019-05-31       Impact factor: 3.199

3.  Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis.

Authors:  Ratnakar Shukla; Ujjala Ghoshal; Tapan N Dhole; Uday C Ghoshal
Journal:  Dig Dis Sci       Date:  2015-03-18       Impact factor: 3.199

4.  Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.

Authors:  Giovanni Barbara; Madhusudan Grover; Premysl Bercik; Maura Corsetti; Uday C Ghoshal; Lena Ohman; Mirjana Rajilić-Stojanović
Journal:  Gastroenterology       Date:  2018-11-28       Impact factor: 22.682

Review 5.  Gastroduodenal mucosal defense.

Authors:  Thomas Kemmerly; Jonathan D Kaunitz
Journal:  Curr Opin Gastroenterol       Date:  2014-11       Impact factor: 3.287

Review 6.  Current and Potential Treatments for Reducing Campylobacter Colonization in Animal Hosts and Disease in Humans.

Authors:  Tylor J Johnson; Janette M Shank; Jeremiah G Johnson
Journal:  Front Microbiol       Date:  2017-03-23       Impact factor: 5.640

Review 7.  Gut Microbiota Shifting in Irritable Bowel Syndrome: The Mysterious Role of Blastocystis sp.

Authors:  Alireza Olyaiee; Amir Sadeghi; Abbas Yadegar; Elnaz Sadat Mirsamadi; Hamed Mirjalali
Journal:  Front Med (Lausanne)       Date:  2022-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.